2025-09-23 - Analysis Report
Okay, here's a report on Intuitive Surgical (ISRG), incorporating all the provided information.

**Report on Intuitive Surgical (ISRG)**

**1. Company Overview:**

Intuitive Surgical Inc. designs, manufactures, and markets the da Vinci surgical system and related instruments and accessories.

**2. Performance vs. S&P 500 (VOO):**

*   **Cumulative Return (ISRG):** 88.17%
*   **Cumulative Return (VOO):** 106.97%
*   **Absolute Deviation:** -19.1% (ISRG underperformed VOO)
*   **Relative Deviation:** 0.2 (Position within the historical range of deviation, indicating ISRG is currently near its worst historical underperformance relative to the VOO)

**3. Alpha/Beta Analysis:**

| Year       | CAGR    | MDD    | Alpha  | Beta  | Cap(B) |
|------------|---------|--------|--------|-------|--------|
| 2015-2017  | 68.0%   | 56.5%  | 39.0%  | 0.0   | 44.2   |
| 2016-2018  | 77.0%   | 63.4%  | 59.0%  | 0.0   | 58.0   |
| 2017-2019  | 81.0%   | 63.4%  | 52.0%  | 0.3   | 71.6   |
| 2018-2020  | 47.0%   | 63.4%  | 28.0%  | 0.2   | 99.1   |
| 2019-2021  | 91.0%   | 63.0%  | 43.0%  | 0.2   | 130.5  |
| 2020-2022  | -3.0%   | 69.9%  | -6.0%  | 0.2   | 96.4   |
| 2021-2023  | -5.0%   | 72.9%  | -23.0% | 0.9   | 122.5  |
| 2022-2024  | 26.0%   | 72.9%  | 0.0%   | 0.9   | 189.6  |
| 2023-2025  | 9.0%    | 72.9%  | -50.0% | 0.7   | 159.4  |

**Analysis:**

*   **CAGR:**  Fluctuates significantly, with high growth periods (2017-2019) followed by periods of decline or slower growth (2020-2025).
*   **MDD:** Maximum Drawdown is consistently high, indicating significant price volatility and risk.
*   **Alpha:** Recent years (2020-2025) show negative Alpha, indicating underperformance relative to the benchmark (S&P 500) on a risk-adjusted basis.  The most recent period (2023-2025) has a notably negative Alpha.
*   **Beta:**  Beta has increased recently, suggesting ISRG's price is becoming more correlated with and sensitive to the overall market.
*   **Cap(B):** Market Cap shows overall growth tendency, but the recent period, 2023-2025, shows it is declined.

**4. Recent Price Action:**

*   **Current Price:** 438.72
*   **Last Market Close:** Price: 444.55, Previous Close: 438.72, Change: 1.33 (Increased volatility)
*   **5-day Moving Average:** 435.34
*   **20-day Moving Average:** 455.93
*   **60-day Moving Average:** 486.69

**Analysis:**

*   The current price is below the 20-day and 60-day moving averages, suggesting a short-term downtrend.
*   However, the current price is above the 5-day moving average, indicating a slight recent upward movement.
*   The recent price jump (previous close vs. last market close) suggests a potential short-term positive catalyst.

**5. Market Risk Indicators & Signals:**

*   **Market Risk Indicator (MRI):** 0.3367 (Low Risk)
*   **RSI:** 34.98 (Approaching oversold territory)
*   **PPO:** -0.311 (Negative, indicating a downtrend)
*   **Hybrid Signal:** cash_0%_Buy 90% of cash (4 shares - Safe - MRI:0.33)
*   **Delta_Previous_Relative_Divergence:** -0.5 (Short-term downward trend)
*   **Expected Return (%):** 4561.3 (Significant long-term outperformance potential vs. S&P 500, given a long-term investment horizon)

**Analysis:**

*   The MRI indicates a low-risk market environment.
*   The RSI approaching oversold territory could suggest a potential buying opportunity.
*   The negative PPO and negative divergence indicate continued short-term weakness.
*   The hybrid signal suggests a moderate buy recommendation.
*   The high expected return suggests significant long-term potential, contrasting with recent underperformance.

**6. Recent News & Significant Events:**

*   **Intuitive Surgical, Inc. (ISRG) Outpaces Stock Market Gains:** (Zacks) - Positive short-term performance relative to the broader market.
*   **How SS Innovations is expanding robotic surgery's reach:** (MedTech Dive) - Competitive landscape development, potentially impacting ISRG's market share in the long term.
*   **These 2 Growth Stocks Have Been Hammered. Time to Buy?:** (Motley Fool) - ISRG considered a potentially undervalued growth stock.
*   **A Fresh Look at Intuitive Surgical (ISRG) Valuation Following New da Vinci 5 Software Innovations:** (Simply Wall St.) - Focus on valuation after new product innovation.
*   **Intuitive Surgical: How To Find & Own America's Greatest Opportunities:** (Investor's Business Daily) - Long-term investment perspective.
*   **Analysts Stay Positive on Intuitive Surgical (ISRG) Despite Stock Dip:** (Insider Monkey) - Continued analyst confidence despite recent price declines.

**Analysis:**

*   Recent news is mixed, with some positive headlines about outperformance and analyst confidence, but also concerns about competition and valuation.
*   The focus on the da Vinci 5 software innovation is a key positive catalyst.
*   The general sentiment is cautiously optimistic, highlighting long-term growth potential despite short-term challenges.

**7. Analyst Opinions:**

*   **Consensus:** Buy (Mean: 1.94)
*   **Target Price:** Average: 582.10, High: 685.00, Low: 350.00
*   **Recent Rating Changes:** Not specified in the provided data.

**Analysis:**

*   Analyst consensus is generally positive, with a "Buy" rating.
*   The average target price suggests significant upside potential.
*   The wide range in target prices reflects uncertainty in the company's future performance.

**8. Earnings Analysis:**

| Date       | EPS  | Revenue   |
|------------|------|-----------|
| 2025-07-23 | 1.84 | 2.44 B$   |
| 2025-04-23 | 1.95 | 2.25 B$   |
| 2024-10-18 | 1.59 | 2.04 B$   |
| 2024-07-19 | 1.48 | 2.01 B$   |
| 2025-07-23 | 1.48 | 2.01 B$   |

**Analysis:**
The latest earnings data displays an inconsistency where the data for 2025-07-23 is duplicated. The available data shows growth in both EPS and Revenue over the recent quarters, indicating positive financial performance.

**9. Financial Information:**

**Revenue and Profitability:**

| Quarter    | Revenue  | Profit Margin |
|------------|----------|---------------|
| 2025-06-30 | $2.44B  | 66.31%        |
| 2025-03-31 | $2.25B  | 64.69%        |
| 2024-12-31 | $2.41B  | 68.04%        |
| 2024-09-30 | $2.04B  | 67.41%        |
| 2024-06-30 | $2.01B  | 68.30%        |

**Capital and Profitability:**

| Quarter    | Equity   | ROE     |
|------------|----------|---------|
| 2025-06-30 | $17.85B | 3.69%   |
| 2025-03-31 | $17.11B | 4.08%   |
| 2024-12-31 | $16.43B | 4.17%   |
| 2024-09-30 | $15.58B | 3.63%   |
| 2024-06-30 | $14.71B | 3.58%   |

**Analysis:**

*   **Revenue:**  Shows consistent growth, indicating increasing demand for ISRG's products and services.
*   **Profit Margin:** Remains consistently high, indicating strong pricing power and efficient operations.
*   **Equity:**  Growing equity base suggests financial stability and reinvestment potential.
*   **ROE:**  Return on Equity is fluctuating slightly, but generally healthy, indicating efficient use of shareholder equity to generate profits.

**10. Summary & Conclusion:**

Intuitive Surgical (ISRG) presents a mixed picture. While it has strong fundamentals (high profit margins, growing revenue, and a healthy ROE), recent performance has lagged the S&P 500.  The stock exhibits high volatility, as reflected in the maximum drawdown figures. Recent news and analyst opinions suggest cautious optimism, with a focus on the company's long-term growth potential, particularly driven by the da Vinci 5 innovation.

**Key Considerations:**

*   **Short-Term Downtrend:**  Technical indicators suggest continued short-term downward pressure.
*   **Long-Term Potential:**  Analysts and the company's fundamentals point to significant long-term growth potential.
*   **Valuation:**  Valuation remains a concern, as indicated by the mixed analyst target prices and the recent news focusing on valuation.
*   **Competition:** The evolving competitive landscape in robotic surgery needs to be monitored.

**Overall Recommendation:**

Given the conflicting signals, a neutral to cautiously optimistic stance is warranted.  Investors should carefully consider their risk tolerance and investment horizon.  A potential strategy could be to accumulate shares gradually, taking advantage of any further price weakness, while remaining aware of the competitive dynamics and valuation concerns. Long-term investors might find the high expected returns attractive, but should be prepared for potential volatility.
